
CONTENTS

Introduction		I
	<i>Jeanne Moldenhauer</i>	
References		II
2	Regulatory Basis for FDA Inspections	13
	<i>Jeanne Moldenhauer</i>	
	Responsibilities of the FDA	13
	Review of New Products	14
	Monitoring Products on the Market	14
	Development of Standards and Regulations	15
	Research Activities	15
	Enforcement Activities	15
	The Food, Drug and Cosmetic Act	16
	The Bill of Rights	17
	Constitutional Challenges to the Authority to Inspect Facilities	17
	FDA Responsibilities	19
	FDA Inspections	20
	FDA Investigators	22
	The FDA Investigator's Role During an Inspection	22
	Regulatory Notes	22
	Team Inspections	23
	FDA's Inspection Preparation	24
	Pre-announcements	24

Notice of Inspection	25
Follow-up Inspections Conducted via Court Order	25
Inspections when Criminal Acts are Contemplated	26
Preliminary Questions Asked	26
Inspectional Approach	26
Typical Inspection Techniques	27
Fact-Finding Mission	28
Sample Collection	29
Interview Techniques	29
Reporting Observations	30
Annotation of the FD-483	31
Wrap-Up Meetings (Discussions with Management)	31
Establishment Investigation Report (EIR)	31
Affidavits	32
Commonly Used FDA Inspection Forms	32
Pre-Approval Inspections (PAIs)	33
Refusing an Inspection	33
References	34
3 Systems-Based Inspections	35
<i>Jeanne Moldenhauer</i>	
Objectives of Systems-based Drug Inspections	36
Strategy	37
Systems for Audit During Inspection	38
Quality System	38
Facilities and Equipment System	39
Materials System	39
The Production System	39
The Packaging and Labeling System	39
The Laboratory Control System	39
Inspection Options	40
Full Inspection Option	40
Abbreviated Inspection Option	40
Selection of the Systems to be Inspected	40
Product Classes	41
Other Types of Inspections	42
Compliance Inspections	42
State of Control	42
Out-of-Control	42
References	42

4	The Quality System	73
	<i>David A. Henninger</i>	
	Introduction	73
	The Quality System — Management Responsibility	75
	Introduction	75
	Design Considerations	75
	Inspection of Management Responsibility	76
	Quality Systems — Drug Product Reviews	83
	Introduction	83
	System Design Considerations	83
	Inspection Guidance	83
	Quality System — Drug Product Complaints	88
	Introduction	88
	System Design Considerations	88
	Inspection Guidance	92
	Quality Systems — Discrepancy and Failure Investigations	100
	Introduction	100
	Design Considerations	100
	Inspection Guidance	101
	Quality Systems — Change Control	105
	Introduction	105
	Design Considerations	105
	Inspection Guidance	110
	Quality Systems — Product Improvement Projects	116
	Introduction	116
	Design Considerations	116
	Inspection Guidance	116
	Quality Systems — Reprocess/Rework	119
	Introduction	119
	Design Considerations	119
	Inspection Guidance	119
	Quality Systems — Returns and Salvage	124
	Introduction	124
	Design Considerations	124
	Inspection Guidance	125
	Quality Systems — Rejects	130
	Introduction	130
	Design Considerations	130
	Inspection Guidance	130
	Quality Systems — Stability Testing	134
	Introduction	134

Design Considerations	134
Inspection Guidance	134
Quality System — Quarantine Products	142
Introduction	142
Design Considerations	142
Inspection Guidance	142
Quality System — Validation and Revalidation	147
Introduction	147
Design Considerations	147
Inspection Guidance	148
Quality System — Training and Qualification of Quality Unit Employees	153
Introduction	153
Design Considerations	153
Inspection Guidance	155
References	159
Bibliography	159
5	The Facilities and Equipment System
	<i>Michael Millin</i>
	163
Facility Design	164
Raw Material Flow	167
Finished Product and Components	167
Lighting	177
Ventilation, Air Filtration, Air Heating and Cooling	178
§211.48 Plumbing	182
Sewage and Refuse	184
Washing and Toilet Facilities	184
Sanitation	185
Maintenance	186
Equipment	187
Equipment Design, Size, and Location	187
Equipment Construction	188
Equipment Cleaning and Maintenance	188
Calibration	190
Automatic, Mechanical, and Electronic Equipment	191
Conduct of the Inspection	192
Critical Concerns	195
References	197

6	The Materials System	203
	<i>Seth Pyers</i>	
	Areas an Inspection is Expected to Cover	203
	Considerations for Assessing Compliance for these Systems	205
	Materials System Overview	205
	Standard Materials	206
	Written and Approved Procedures	206
	Training and Qualification of Personnel	207
	Identification of Components, Containers and Closures	207
	Inventory of Components, Containers and Closures	207
	Storage Conditions	207
	Quarantine of Materials until Tested and/or Examined	207
	Specific Identity Testes for Each Lot of Components	208
	Visual Identification Test for Each Lot	208
	Validation of Vendor Supplied Test Results	208
	Materials are Rejected when Criteria are not Met	208
	Determine When and How to Retest Lots of Materials	208
	Procedures Ensure First-In-First-Out of Components	208
	Surfaces, Containers and Products are Mutually	
	Non-Reactive	209
	Change Control	209
	Inventory Control Software	209
	Part II Compliance for Automated Data Handling Systems	210
	Record All Finished Products by Lots	211
	Document Investigations	211
	Utility Provided Materials	212
	Water Production Sources	212
	Guide to Inspection High Purity Water Systems	213
	Systems Design	213
	Microbial Limits USP High Purity and WFI Hot, Cold	
	and Ambient	213
	Pretreatment	214
	Flocculation	214
	Reverse Osmosis	215
	Distillation	216
	Biofilms	219
	High Purity Water Systems Validation	224
	Inspection Strategy	225
	Clean Steam Systems	226
	Solvents	226
	Medical Grade Gases	227

Examples of Significant and/or Trend of Deficiencies	227
Recent Regulatory Findings	228
References	228
7 The Production System	231
<i>Michele Conway and Robert Ferer</i>	
Training/Qualification of Personnel	233
Control System for Implementing Changes in Process	234
Adequate Procedure and Practice for Charge-in of Components	236
Formulation/Manufacturing at Not Less Than 100%	237
Identification of Equipment with Contents, and Where	
Appropriate Phase of Manufacturing and/or Status	238
Validation and Verification of Cleaning/Sterilization/ Depyrogenation of Containers and Closures	239
Calculation and Documentation of Actual Yields and Percentage of Theoretical Yields	241
Contemporaneous and Complete Batch Production Documentation	242
Established Time Limits for Completion of Phases of Production	243
Implementation and Documentation of In-Process Controls, Tests, and Examinations (e.g., pH, adequacy of mix, weight variation, clarity)	244
Justification and Consistency of In-Process Specifications and Drug Final Specifications	245
Prevention of Objectionable Microorganisms in Non-Sterile Drug Products	246
Adherence of Preprocessing Procedures (e.g., set-up, line clearance, etc.)	247
Equipment Cleaning and Use Logs	248
Master Production and Control Records/Batch Production and Control Records	249
Process Validation, Including Validation and Security of Computerized or Automated Processes	250
Change Control: The Need for Revalidation Evaluated	252
Documented Investigation into any Unexpected Discrepancy	253
References	254

8	The Packaging and Labeling System	257
	<i>Jeanne Moldenhauer</i>	
	Areas Expected to be Covered in an Inspection	257
	Considerations for Assessing Compliance for these Systems	259
	Evidence of Written Procedures	259
	Training and Qualification of all Affected Personnel	259
	Procedure for Acceptance of Packaging and Labeling Materials	259
	Effective Change Control System for Implementing Changes in Packaging and Labeling Operations	260
	Adequate Storage for Labels and Labeling (both approved and those returned after Issuance)	260
	Control of Labels that are Similar in Size, Shape, and Color for Different Products at the Site	261
	If Cut Labels are used for Finished Products for Immediate Containers that are Similar in Appearance without Some Type of 100% Electronic or Visual Verification System or Use of Dedicated Lines	261
	Verification that Gang Printing of Labels is Not Performed, Unless the Labels are Differentiated by Size, Shape or Color	261
	Control Procedures are Established and Followed if Filled Unlabeled Containers are Produced that are Later Labeled under Multiple Private Labels	262
	Adequate Packaging Records are Available that Include Specimens of All Labels Used for Each Product and Lot	262
	Control Procedures are Established and Followed for Issuance of Labeling, and that there is Appropriate Examination of Issued Labels and Reconciliation of Used Labels	262
	Examination of Labeled Finished Product is Conducted	262
	Adequate Inspection (proofing) of Incoming Labeling Materials	263
	Appropriate Use of Lot Numbers on Labels, and Destruction of Excess Labeling Bearing Lot or Control Numbers	263
	Physical and/or Spatial Separation Exists Between Different Labeling and Packaging Lines	263
	Monitoring of Printing Devices Associated with Manufacturing Lines is Conducted	279
	Line Clearance and Inspection is Performed and Documented	263

x *Systems-Based Inspections for Pharmaceutical Manufacturers*

Adequate Expiration Dates are Present on the Label	264
Conformance to Tamper-Evident Packaging (TEP) Requirements, as Required per 21 CFR §211.132 and Compliance Policy Guide No. 7132a.17	264
Appropriate Validation of Packaging and Labeling Operations is Conducted including Validation and Security of Computerized Processes	264
Documented Investigations are Performed for any Unexpected Discrepancy	264
Examples of Significant and/or Trend of Deficiencies	265
Recent Regulatory Findings	265
References	265

9 The Laboratory System 267*Jeanne Moldenhauer*

Areas Expected to be Covered in an Inspection	267
Evidence of Written Procedures	269
Training and Qualification of all Affected Personnel	269
Adequacy of Staffing for Laboratory Operations	269
Adequacy of Equipment and Facility for Intended Use	270
Calibration and Maintenance Programs for Analytical Instruments and Equipment	271
Validation and Security of Computerized or Automated Processes	272
Reference to Standards, Source, Purity and Assay, and Tests Establish Equivalency to Current Official Reference Standards, as Appropriate	272
System Suitability Checks on Chromatographic Systems (e.g., GC or HPLC)	273
Specifications, Standards, and Representative Sampling Plans	273
Adherence to the Written Methods of Analysis	273
Validation or Verification of Analytical Methods	273
Control System for Implementing Changes in Laboratory Operations	274
Required Testing is Performed on the Correct Samples	275
Documented Investigation into any Unexpected Discrepancy	275
Complete Analytical Records from All Tests and Summaries of Results	275
Quality and Retention of Raw Data (e.g., chromatographs and spectra)	276

	Correlation of Result Summaries to Raw Data; Presence of Unused Data	276
	Adherence to an Adequate OOS Procedure which includes Timely Completion of the Investigation	276
	Adequate Reserve Samples; Documentation of Reserve Sample Examination	277
	Stability Testing Program, including Demonstration of Stability Indicating Capability of the Test Methods	277
	Examples of Significant and/or Trend of Deficiencies	277
	Recent Regulatory Findings	278
	Issues with Procedures for OOS	286
	Environmental Monitoring and Control Issues	386
	Media Fill Observations	286
	Reference	287
10	Evaluating Your Facility for Compliance	289
	<i>Jeanne Moldenhauer</i>	
	Who Should Perform Assessments	290
	Typical Assessment Procedures	290
	Audit Preparation	290
	During the Audit	291
	Completing the Assessment	292
	Assessment Report	292
	Assessment Follow-Up	292
	Retention of Assessment Reports	293
	Example of an Audit Checklist	294
11	Preparing for a FDA Systems-Based Inspection	323
	<i>Jeanne Moldenhauer</i>	
	Why Prepare?	323
	Historical Methods Used for Inspection Preparation	324
	The Current Situation	325
	Identify Key Employees and Train Them	326
	Interacting with the FDA During the Inspection	327
	What to Expect During the Interview Process	328
	Aids to Training and Answering Questions During the Audit	328
	History of Company and Organization Changes	328
	Flow Charts	329

xii *Systems-Based Inspections for Pharmaceutical Manufacturers*

Sterile Process Validation Documentation Packages	330
Key indices	330
Standardization of Documentation	330
Technical Glossary	330
Questions to Ask the FDA	331
Information that Should be Conveyed to the Inspector	331
Practice Tours of the Facility	332
Self-Audit and Know Your Vulnerabilities	332
Prepare for the FDA Areas of Focus	333
Inspectional Guidance Documents	333
Know Your Company's Policies	334
Documentation	334
Requests for Samples	335
Mock Inspections	336
I Know I Have a Problem. Now What?	336
Simple Rules of Etiquette to Use During an Inspection	337
Handling Difficult Inspectors	338
Learn from the Mistakes of Others	339
Observations for the Quality System	339
Observations for the Laboratory System	340
Observations for the Facilities and Equipment System	340
Observations for the Production System	340
Acknowledgements	341
References	341
12	Managing of Regulatory Inspections
	<i>Jeanne Moldenhauer</i>
Who May Inspect the Facility?	345
What Requirements Allow the Government Inspection?	336
What is the Purpose of the Audit?	347
Are There Company Policies or Procedures that will Define What Investigators May Do During the Inspection?	348
What's Your Job?	349
How Do I Handle Documentation?	351
What Could Go Wrong?	351
Conclusion	351
Acknowledgements	351

13	Concluding an Inspection and Handling Inspection Findings	353
	<i>Jeanne Moldenhauer</i>	
	The Exit Discussion	354
	Reporting of Observations, the FDA-483	355
	General Principles for FDA-483 Observations	355
	Annotation of Observations	356
	Impact of these Observations	356
	Freedom of Information (FOI)	356
	Writing Observations	357
	Triggers to Observations	357
	Non-reportable Observations	358
	Determining the Significance of FDA-483 Observations	358
	Handling Adverse Findings	359
	Written Response to the FDA-483	359
	Dispute Resolution	360
	Evaluation Compliance with Corrective Action Program	
	Established	360
	Warning Letters	361
	On-going Evaluations	361
	References	361
	Glossary	363
	Author Biographies	373
	Index	

